arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

INTENSITY THERAPEUTICS, INC.

INTS
$4.31 ▲ +0.06 (+1.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
5 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTENSITY THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -79.6%
FCF / Share $-6.81
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-11.61M
↑ +28.7%
FCF / Share Free cash flow per share
$-6.81
↑ +75.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters